Milea Timbergen

239 References 1 . World Health Organization, International statistical classification of diseases and related health problems, 10th revision, volume 3 2016 [fifth edition 2016: Available from :http://apps.who.int/iris/bitstream/handle/10665/246208/9789241549165-V3-eng. pdf?sequence=3&isAllowed=y&ua=1. 2 . van Broekhoven DL, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. 3 . De Marchis ML, Tonelli F, Quaresmini D, Lovero D, Della-morte D, Silvestris F, et al. Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Res. 2017(37):3357-3336. 4 . Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). European Journal of Surgical Oncology. 2009;35(1):3-10. 5 . Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151(2):230-237. 6 . Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, et al. β-catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013;18(9):1043-1049. 7 . van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22(5):1464-1470. 8 . Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, et al. Desmoid-type fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. Annals of Surgery. 2014;259(5):973-978. 9 . Sleijfer S. Management of aggressive fibromatosis: can we unravel the maze of treatment options? Eur J Cancer. 2009;45(17):2928-2929. 10 . Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. European Journal of Cancer. 2015:186-192. 11 . Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29(26):3553-3558. 12 . Al-Jazrawe M, Au M, Alman B. Optimal therapy for desmoid tumors: current options and challenges for the future. Expert Rev Anticancer Ther. 2015;15(12):1443-1458. 13 . Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131. 14 . van Broekhoven DL, Grunhagenl DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, et al. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. BMC Cancer. 2016;16(1):686. 15 . Landelijke Richtlijn Wekedelen Tumoren, versie 2.0 (2011): Oncoline, richtlijnen oncologische zorg; 2011 Available from: http://www.oncoline.nl/wekedelentumoren. 16 . Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096-4102. 17 . Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and recurrence patterns of desmoids tumors: A multi-institutional analysis of 211 patients. Annals of Surgical Oncology. 2012;19(13):4036-4042. 18 . Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60-67. 8